KEYNOTE-177 & CheckMate 142: checkpoint blockade in MSI-H/dMMR CRC Published 2021-01-19 Download video MP4 360p Download video MP4 720p Recommendations 01:53 Immunotherapy and Targeted Therapy in Colorectal Cancer: 2023 Best of GI 03:58 16+ Years Cancer-Free Thanks to Immunotherapy: Sharon Belvin's Melanoma Story 06:04 Dr. Toni Choueiri Discusses Belzutifan's FDA Approval: A Game-Changer for Clear Cell Kidney Cancer 1:27:19 The Art of Aging Well 35:42 Immunotherapy in CRC | 2023 Best of GI Cancer Conference 1:32:45 Turning Fear into Power: Understanding and managing anxiety - Longwood Seminar 01:16 KEYNOTE-057 cohort C: pembrolizumab with favezelimab or vibostolimab in NMIBC 16:07 Shock Explained Clearly - Cardiogenic, Hypovolemic, and Septic 06:35 Explaining the pathology of Lynch Syndrome 01:14 Current and future trends in immunotherapy for MSI-H colorectal cancer 1:28:26 Cancer Metabolism: From molecules to medicine 1:07:16 Guidelines for Performing a Comprehensive Transesophageal Echocardiographic Examination 01:58 What’s next for antibody drug conjugates in urothelial carcinoma? 03:01 Cancer Care in the Hospice Setting 02:10 Can a stage 4 colon or rectum cancer be treated or cured? | Dr. Sandeep Nayak 37:33 Introducing MRI: Generating an NMR Signal: Resonance and Excitation (7 of 56) 14:38 Mechanical Ventilation Explained Clearly by MedCram.com | 4 of 5 01:51 Cardiovascular events in patients with prostate cancer treated with ADT 00:51 Advances in immunotherapy for rectal cancer 08:36 Lynch Syndrome (Hereditary Nonpolyposis Colorectal cancer or HNPCC) | Pathology | 5-Minute-Review Similar videos 01:04 Dr. Halfdanarson on the KEYNOTE-177 Trial in MSI-H/dMMR mCRC 02:56 KEYNOTE-177: final PFS analysis of pembrolizumab in patients with MSI-H/dMMR mCRC 01:08 Dr. Ahn on the KEYNOTE-177 Trial in Newly Diagnosed MSI-H/dMMR mCRC 02:55 Analysis of HLA gene expression in dMMR/MSI-H, ICI-resistant CRC 02:37 Moving Forward With Results From CheckMate-142 in MSI-H mCRC 06:57 KEYNOTE-177 discussion: chemo-immunotherapy, pseudoprogression & biomarkers 01:34 CheckMate-142: Updated data from MSI high metastatic colon cancer patients 02:03 Promising CheckMate-142 Data for Second-Line Ipilimumab Plus Nivolumab in mCRC 02:22 KEYNOTE-177 03:17 D.M.M.R 02:32 Dr. Overman Discusses Updated Findings of CheckMate-142 in Patients With MSI-H mCRC 05:35 Howard Hochster, MD, discusses the outcomes of the Keynote-177 study in metastatic CRC 01:54 Dr. Lenz on Updated Data From CheckMate 142 With Nivolumab + Ipilimumab in mCRC 00:53 Dr. Lenz on the Safety Profile of CheckMate-142 Trial in CRC 07:37 Dr. Nazik Hammad presents Keynote-177 (GI cancer) 59:51 Redefining First- line Therapy in Metastatic Colon Cancer. The Keynote-177 Study. 04:39 Tanios Bekaii-Saab, MD, FACP, offers opinion on the updated KEYNOTE-177 as presented at ASCO GI 2021 01:35 Dr. Chu on the Role of Pembrolizumab in dMMR/MSI-H mCRC More results